Colon Cancer Treatment May Be More Toxic Than Thought
And it's the same advice Saltz and the letter authors give. "Vigilant monitoring of all patients who are receiving this combination ... is called for because specific clinical factors that increase the risk of adverse effects have not yet been identified," write the letter authors.
But they also write that because the regimen improved survival in patients with advanced colorectal cancer in the earlier study, the triple-drug therapy should continue to be an option.
Meanwhile, both trials continue, with slight modifications, so patients can be treated and the researchers can fine-tune their knowledge of Camptosar.